Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety, tolerance and efficacy of
Utidelone combined with Anlotinib in patients with Advanced or Recurrent Esophageal Carcinoma
who failed Standard first line therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Peking University
Collaborators:
Beijing Biostar Pharmaceuticals Co., Ltd. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.